Hervé Affagard

Company: Maat Pharma

Job title: Co-Founder & Chief Executive Officer

Seminars:

MaaT013: The First Phase 3 Trial for Microbiome Therapy in Hemato-Oncology 9:30 am

Discussing the ongoing pivotal Phase 3 ARES trial for MaaT013 in patients with acute Graft-versus-Host Disease (GI-aGvHD) and its significance as the first global Phase 3 trial for a microbiome-based therapy in hemato-oncology Highlighting the Orphan Drug Designation from both the FDA and EMA, and the positive outcomes from the Data Safety Monitoring Board (DSMB)…Read more

day: Conference Day One - 7am to 10am

Roundtable: Advancing Microbiome Therapeutics: Insights from the MTIG and EMIH Collaboration 8:00 am

How can harmonized regulatory frameworks benefit microbiome therapeutics across different regions, and what specific steps can be taken to achieve this harmonization? What innovative strategies can be employed to accelerate the development of microbiome-based therapies through international collaboration, and how can these strategies be effectively implemented? How can expanding access to microbiome therapies benefit the…Read more

day: Conference Day Two, 7:30 - 10:00